Business
Interim results from this Phase II/III trial and final results from the prior Phase II trial in psoriasis were both positive
Hi, what are you looking for?
Jewish Business News
Business
Teva is selling four targeted oncology development programs to Ignyta for 6% of the biotech company.
Business
G&W Pharmaceuticals will have the right to produce and sell some of Teva's products
Bio-Tech
"With this financing in place, we are well positioned to advance a portfolio of oral drugs that address unmet needs in orphan indications."
Business
PayPal and credit card companies's refusal to deal with legal pot creates headaches for those in the industry
Business
RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK.
Business
"We are excited to start operating in the South Korean market, as it has a strong focus on patient safety and quality of care."
Business
The Rod Show will be held on Thursday, March 12.
Business
"Nearly 100 million diabetes patients need to monitor their glucose daily. The GlucoTrack model DF-F gives Chinese diabetic patients an alternative way to check...
Business
Company just completed Phase II/III psoriasis trial and expects to release top line data in Q1 2015